Syndax Announces Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Selected as Late-Breaking Presentation at the 65th ASH Annual Meeting lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.
– NDA submission initiated for revumenib in R/R KMT2Ar acute leukemia under RTOR – – mNPM1 final efficacy data from the Phase 1 portion of AUGMENT-101.
Fred Hutchinson Cancer Center provides symposiums, webinars and other educational programs about specific disease programs focusing on advancements to diagnostic techniques and treatment modalities. Our programs feature physician speakers from Fred Hutch, UW Medicine and Seattle Children’s.
FDA issues guidance and recommendations for New Drug Applications (NDA) and Biologic Laboratory Applications (BLA) which implicate oncology therapies and warrant Real-time Oncology Review (RTOR).